top of page

Free Biopharma Daily Stock Updates - 08/12/21

$XBI $126.79 +0.9%


Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!


Pipeline Updates

$FUSN +1.2% Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production. source

$JAZZ +0.4% Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults. source

$VYNE -31.1% VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited. source

$ALLO -0.4% Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM). source

$CHRS +2.0% Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma. source

$LQDA +9.3% U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics’ Tyvaso® Patent. source

$PHAS -1.5% PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor. source

$APRE -1.5% Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program. source

$ANGN -18.2% Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results. source

$NOVN +15.4% Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update. source

$LRMR +17.85 Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results. source

$SESN +21.5% Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum™. source

Financial Updates

$CRMD +0.7% The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OCGN, CRMD and AHCO. source

$CALT -2.9% Calliditas Therapeutics intends to carry out a directed share issue. source

$FULC +11.1% Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock. source


Posted by FS

bottom of page